AVBP Latest Press Releases

-- October 21, 2026 --

ARRIVENT BIOPHARMA AVBP INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 47.3% Share Drop Business Wire 6:00 PM

-- October 19, 2026 --

ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer Globe Newswire 8:01 AM

-- October 13, 2026 --

ARRIVENT BIOPHARMA INVESTIGATION: AVBP Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights Globe Newswire 3:42 PM

ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky PRNewswire 3:11 PM

-- October 12, 2026 --

ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002 Globe Newswire 4:01 PM

-- October 9, 2026 --

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving ArriVent BioPharma (AVBP) Globe Newswire 10:13 AM

-- October 8, 2026 --

AVBP Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into ArriVent BioPharma (AVBP) ACCESS Newswire 10:25 AM

-- October 7, 2026 --

AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law Business Wire 10:56 PM

AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma PRNewswire 2:21 PM

-- October 6, 2026 --

ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP) PRNewswire 5:48 PM

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC Globe Newswire 8:00 AM

-- August 12, 2026 --

ArriVent BioPharma Reports Second Quarter 2026 Financial Results Globe Newswire 4:01 PM

Market Data Delayed 15 Minutes